Anxiolytics

Austria Modern Oral Tobacco Products Market report 2021 - ResearchAndMarkets.com

Retrieved on: 
금요일, 7월 16, 2021

The "Market Report: Modern Oral Products in Austria" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Report: Modern Oral Products in Austria" report has been added to ResearchAndMarkets.com's offering.
  • Nicotine pouches are widely available in Austria both online and offline.
  • This report is based on our survey and analysis of both the online and offline modern oral markets.
  • It includes information on availability of modern oral products, top brands, product characteristics such as most available flavour categories and most available nicotine strengths, and pricing information.

Next Generation Labs Granted European Patent for TFN® Synthetic Nicotine Manufacturing Process Further Strengthening IP Enforcement Efforts Against TFN® Violators

Retrieved on: 
월요일, 6월 28, 2021

3209653), for its proprietary technology related to the preparation of R-S isomer nicotine.

Key Points: 
  • 3209653), for its proprietary technology related to the preparation of R-S isomer nicotine.
  • "This patent grant by the European Patent Office is a significant milestone for Next Generation Labs, as it solidifies our tobacco-free synthetic nicotine intellectual property portfolio across a number of European countries, allowing the Company to better enforce its rights against violators and counterfeiters of its industry leading TFN branded synthetic nicotine.
  • About Next Generation Labs ('NGL'): Since 2014 NGL has been the world's largest manufacturer of S-isomer, combinational R/S isomer and R-isomer synthetic nicotine under the federally-registered brand name TFN.
  • NGL's TFN products are manufactured under strict conditions to meet cGMP, USP and EU standards to achieve a level of 99.97% pure synthetic nicotine.

22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives

Retrieved on: 
금요일, 6월 25, 2021

It has now been just over one year since I was appointed CEO of 22nd Century Group, and I would like to thank you for your enthusiasm and support of our Company.

Key Points: 
  • It has now been just over one year since I was appointed CEO of 22nd Century Group, and I would like to thank you for your enthusiasm and support of our Company.
  • Shares of 22nd Century have soared over 470% in the past 12 months.
  • The new technology provides 22nd Century with a rapid pathway to introduce reduced nicotine traits into virtually all varieties of tobacco.
  • 22nd Century has reached a true inflection point in our business -- and the best is yet to come.

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

Retrieved on: 
목요일, 6월 24, 2021

This analysis provided the rationale for the design of Monopars Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.

Key Points: 
  • This analysis provided the rationale for the design of Monopars Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.
  • For information on registration, visit: https://www.mascc.org/2021-registration
    Validive (clonidine mucobuccal tablet; clonidine MBT) is a novel mucobuccal tablet (MBT) formulation.
  • The mucobuccal tablet provides for prolonged and enhanced local delivery of clonidine to the regions of oral mucosal radiation damage in OPC patients.
  • Examples of these forward-looking statements include: the Companys excitement for the opportunity to continue working towards providing a treatment for severe oral mucositis; and the Phase 2 trial supporting further clinical development in patients with oropharyngeal cancer.

Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

Retrieved on: 
목요일, 6월 10, 2021

Specifically, inhibitors of PDE7 reduced nicotine consumption and relapse in rodent models of nicotine abuse.

Key Points: 
  • Specifically, inhibitors of PDE7 reduced nicotine consumption and relapse in rodent models of nicotine abuse.
  • The research was conducted in collaboration with the School of Pharmacy of the University of Camerino in Italy.
  • Recent developments such as forms of electronic nicotine delivery are contributing to a new surge of nicotine use, especially in young adults.
  • Omeros owns global rights to the use of PDE7 inhibitors for the treatment of addictive disorders.

VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder

Retrieved on: 
수요일, 5월 26, 2021

Initiation of PALISADE-1 is a major milestone for our PALISADE Phase 3 clinical program for PH94B, a program aimed at supporting a potential New Drug Application to the FDA.

Key Points: 
  • Initiation of PALISADE-1 is a major milestone for our PALISADE Phase 3 clinical program for PH94B, a program aimed at supporting a potential New Drug Application to the FDA.
  • The PALISADE-1 Phase 3 trial design is substantially based upon the design of the laboratory-simulated public speaking challenge in the Phase 2 multi-center, randomized, double-blind, placebo-controlled trial of PH94B for the acute treatment of anxiety in adults with SAD.
  • In that Phase 2 study, PH94B rapidly reduced (within 15 minutes) anxiety in response to both the public speaking challenge (p=0.002) and a social interaction challenge (p=0.009).
  • Following successful Phase 2 development, VistaGen has recently initiated its PALISADE-1 Phase 3 clinical trial of PH94B for acute treatment of anxiety in adults with SAD.

22nd Century VP of Regulatory Science to Present on Health Disparities Caused by Cigarette Addiction at FDLI Annual Conference

Retrieved on: 
화요일, 5월 18, 2021

The session will focus on the health disparities caused by tobacco and nicotine products among different groups within society, including a review of the use of mentholated products and their disproportionately high impact on African Americans.

Key Points: 
  • The session will focus on the health disparities caused by tobacco and nicotine products among different groups within society, including a review of the use of mentholated products and their disproportionately high impact on African Americans.
  • With our VLN\xc2\xae King and VLN\xc2\xae Menthol King reduced nicotine content (RNC) cigarettes, 22nd Century provides the only combustible tobacco products able to meet the nicotine level in the FDA\xe2\x80\x99s proposed mandate.
  • The feasibility of a low nicotine product standard is clear, the science is clear, and the benefits to our society are clear.
  • Public health can and must be advanced and we must ensure that no one in our society is left behind,\xe2\x80\x9d said John Pritchard.

Survey: 55% Packed On "Pandemic Pounds"

Retrieved on: 
월요일, 5월 17, 2021

Pandemic life left many stressed, drinking more alcohol, gaining weight and in need of a break.

Key Points: 
  • Pandemic life left many stressed, drinking more alcohol, gaining weight and in need of a break.
  • 31% admit their alcohol consumption increased during the pandemic, that\'s a 29% increase from May 2020.
  • However, all the extra family time has been a silver lining for some relationships.
  • While 38% report having resumed "normal life"; 64% think all of the current COVID-19 restrictions are necessary to be kept in place.

CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep Gummies

Retrieved on: 
화요일, 5월 11, 2021

Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood.

Key Points: 
  • Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood.
  • L-Theanine is an amino acid found in green tea that has been extensively researched for stress management.
  • PlusCBD\xe2\x84\xa2 Calm and Sleep gummies contain no artificial flavoring or sweeteners, making them an attractive option for those looking to support their stress response and sleep cycle without artificial additives.
  • \xe2\x80\x9cOur Calm and Sleep gummies underscore the Company\xe2\x80\x99s ongoing commitment to advancing the CBD industry through science-backed formulations.\xe2\x80\x9d\nCV, or Curriculum Vitae, is Latin for \xe2\x80\x9ccourse of life\xe2\x80\x9d, and science is the pursuit of truth.

Bionomics BNC210 Expansion into Social Anxiety Disorder

Retrieved on: 
월요일, 5월 10, 2021

The slow absorption of the liquid suspension formulation of BNC210 and the requirement for it to be taken with food for optimal absorption limited its use for the acute treatment of anxiety in patients with SAD.

Key Points: 
  • The slow absorption of the liquid suspension formulation of BNC210 and the requirement for it to be taken with food for optimal absorption limited its use for the acute treatment of anxiety in patients with SAD.
  • A new solid dose tablet formulation of BNC210 has been successfully developed, showing much improved and rapid absorption over the previous liquid suspension formulation, and will be used for the Phase 2 efficacy clinical trials in SAD and PTSD.\n"Anxiety disorders are a significant burden for our communities and approximately 17 million American adults suffer from Social Anxiety Disorder.
  • Premier Research is recognised as a leading CRO supporting industry-sponsored PTSD studies and has conducted ~10 studies in this indication since 2014, including Bionomics\' RESTORE trial.
  • Collaborating again with Bionomics is the ideal way to leverage ourcollective experience in this space," said Krista Armstrong, PhD, Premier Research SVP, Clinical Development Services & Global Head of Neuroscience.